Disease trajectories and its association with metabolic dysfunction of prostate cancer men following androgen deprivation therapy and the potential of pharmacological medication in preventing metastatic diseases.(2/3)

Medicine & Life Sciences

1. Androgens 100%
2. Prostatic Neoplasms 60%
3. Hyperlipidemias 44%
4. Taiwan 32%
5. Metabolic Syndrome 30%
6. Hypertension 28%
7. Therapeutics 26%
8. Androgen Antagonists 14%
9. Chemoprevention 12%
10. Physiologic Monitoring 11%
11. National Health Programs 11%
12. Palliative Care 10%
13. Disease Progression 8%
14. Comorbidity 8%
15. Cohort Studies 7%
16. Pharmacology 7%
17. Neoplasms 7%
18. Guidelines 7%
19. Databases 6%
20. Mortality 5%